The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rubio, M.-T.
Right arrow Articles by Sykes, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rubio, M.-T.
Right arrow Articles by Sykes, M.
The Journal of Immunology, 2005, 175: 665-676.
Copyright © 2005 by The American Association of Immunologists

Mechanisms of the Antitumor Responses and Host-versus-Graft Reactions Induced by Recipient Leukocyte Infusions in Mixed Chimeras Prepared with Nonmyeloablative Conditioning: A Critical Role for Recipient CD4+ T Cells and Recipient Leukocyte Infusion-Derived IFN-{gamma}-Producing CD8+ T Cells1

Marie-Therese Rubio, Toshiki I. Saito, Kristin Kattleman, Guiling Zhao, Jennifer Buchli and Megan Sykes2

Transplantation Biology Research Center, Bone Marrow Transplantation Section, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129

Surprisingly, antitumor responses can occur in patients who reject donor grafts following nonmyeloablative hemopoietic cell transplantation. In murine mixed chimeras prepared with nonmyeloablative conditioning, we previously showed that recipient leukocyte infusions (RLI) induced loss of donor chimerism, IFN-{gamma} production, and antitumor responses against host-type tumors. However, the mechanisms behind this phenomenon remain to be determined. We now demonstrate that the effects of RLI are mediated by distinct and complex mechanisms. Donor marrow rejection is induced by RLI-derived alloactivated T cells, which activate non-RLI-derived, recipient IFN-{gamma}-producing cells. RLI-derived CD8 T cells induce the production of IFN-{gamma} by both RLI and non-RLI-derived recipient cells. The antitumor responses of RLI involve mainly RLI-derived IFN-{gamma}-producing CD8 T cells and recipient-derived CD4 T cells and do not involve donor T cells. The pathways of donor marrow and tumor rejection lead to the development of tumor-specific cell-mediated cytotoxic responses that are not due to bystander killing by alloreactive T cells.




This article has been cited by other articles:


Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
T. I. Saito and M. Sykes
NK1.1+ Cells Are Involved in the Anti-Tumor Immunity Induced by the Rejection of Donor Hematopoietic Cells in Mixed Bone Marrow Chimeras.
Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 3166 - 3166.
[Abstract] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
T. I. Saito and M. Sykes
Long-Lasting Anti-Tumor Immunity Induced by the Rejection of Donor Hematopoietic Cells in Mixed Bone Marrow Chimeras.
Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 1319 - 1319.
[Abstract]

Home page
 ASH Education BookHome page
T. R. Spitzer
Haploidentical Stem Cell Transplantation: The Always Present but Overlooked Donor
Hematology, January 1, 2005; 2005(1): 390 - 395.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.